Toll Free: 1-888-928-9744
Published: Mar, 2014 | Pages:
39 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Digna Biotech, S.L. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Digna Biotech, S.L. - Product Pipeline Review - 2014', provides an overview of the Digna Biotech, S.L.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Digna Biotech, S.L.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Digna Biotech, S.L. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Digna Biotech, S.L.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Digna Biotech, S.L.'s pipeline products Reasons to buy - Evaluate Digna Biotech, S.L.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Digna Biotech, S.L. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Digna Biotech, S.L.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Digna Biotech, S.L. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Digna Biotech, S.L. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Digna Biotech, S.L. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Digna Biotech, S.L. Snapshot 5 Digna Biotech, S.L. Overview 5 Key Information 5 Key Facts 5 Digna Biotech, S.L. - Research and Development Overview 6 Key Therapeutic Areas 6 Digna Biotech, S.L. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Digna Biotech, S.L. - Pipeline Products Glance 13 Digna Biotech, S.L. - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Digna Biotech, S.L. - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 Digna Biotech, S.L. - Drug Profiles 17 cardiotrophin-1 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 disitertide 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Interferon Alfa-5 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 DB-017 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 DB-029.01 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 DB-055 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Extra Domain A 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 methylthioadenosine 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 oncostatin M 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 P-17 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 DB-027 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Digna Biotech, S.L. - Pipeline Analysis 30 Digna Biotech, S.L. - Pipeline Products by Target 30 Digna Biotech, S.L. - Pipeline Products by Route of Administration 31 Digna Biotech, S.L. - Pipeline Products by Molecule Type 32 Digna Biotech, S.L. - Pipeline Products by Mechanism of Action 33 Digna Biotech, S.L. - Recent Pipeline Updates 35 Digna Biotech, S.L. - Dormant Projects 36 Digna Biotech, S.L. - Locations And Subsidiaries 37 Head Office 37 Other Locations & Subsidiaries 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 39 Disclaimer 39
List of Tables Digna Biotech, S.L., Key Information 5 Digna Biotech, S.L., Key Facts 5 Digna Biotech, S.L. - Pipeline by Indication, 2014 7 Digna Biotech, S.L. - Pipeline by Stage of Development, 2014 9 Digna Biotech, S.L. - Monotherapy Products in Pipeline, 2014 10 Digna Biotech, S.L. - Partnered Products in Pipeline, 2014 11 Digna Biotech, S.L. - Partnered Products/ Combination Treatment Modalities, 2014 12 Digna Biotech, S.L. - Phase II, 2014 13 Digna Biotech, S.L. - Phase I, 2014 14 Digna Biotech, S.L. - Preclinical, 2014 15 Digna Biotech, S.L. - Discovery, 2014 16 Digna Biotech, S.L. - Pipeline by Target, 2014 30 Digna Biotech, S.L. - Pipeline by Route of Administration, 2014 31 Digna Biotech, S.L. - Pipeline by Molecule Type, 2014 32 Digna Biotech, S.L. - Pipeline Products by Mechanism of Action, 2014 34 Digna Biotech, S.L. - Recent Pipeline Updates, 2014 35 Digna Biotech, S.L. - Dormant Developmental Projects,2014 36 Digna Biotech, S.L., Other Locations 37 Digna Biotech, S.L., Subsidiaries 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.